Shares of Eli Lilly & Co. LLY shed 6.45% to $738.21 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 5.97% to 5,074.08 and Dow ...

Sources: FactSet, Dow Jones Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet ...

Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 1458 ET – Eli Lilly’s LillyDirect expansion is a positive step as access to adequate providers remains a barrier ...

Sources: FactSet, Dow Jones Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet ...

On the other hand, the Dow registered ... an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.07% lower. Eli Lilly is currently a ...

EDT, the S&P 500 was up 0.70%. The Dow Jones Industrial Average rose 0.45%, and the Nasdaq Composite was 1.46% higher.

Eli Lilly on Sunday said the Phase 2 study of lepodisiran, designed to lower the production of lipoprotein(a), or lp(a), met its primary endpoint, reducing lp(a) levels by an average of 93.9% over ...

Eli Lilly (LLY) and Company announced positive ... In the Phase 2 ALPACA study, lepodisiran significantly reduced Lpa levels by an average of 93.9% over the 60 to 180-day period after treatment ...

Eli Lilly & Co. closed 18.86% short of its 52-week high of $972.53, which the company reached on August 22nd.